PROTEINA
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx.
PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.”
PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be soon published in a high-profile scientific journal, Nature Biomedical Engineering, later this year.
Starting in May, PROTEINA will transport its Pi-View analysis device and related reagents to labs at Emory. Dr. Janghee Woo, a hematologist at Emory, has spearheaded a translational research laboratory focused on deciphering the molecular mechanisms underlying hematological malignancies to improve clinical outcomes. This endeavor entails the collection and examination of several hundred AML samples to investigate the molecular intricacies of the disease and pinpoint biomarkers linked to therapeutic response. PROTEINA and Dr. Woo’s research team will analyze these samples using the PPI PathFinder BCL2 Dx to validate its clinical efficacy.
Dr. Janghee Woo expressed optimism, stating, “This project will not only validate the clinical efficacy of the PPI PathFinder but also allow for collaboration across various fields through the expansion of solutions to further indications of Venetoclax.”
PROTEINA’s CEO, Tae-Young Yoon, remarked, “Having successfully completed domestic clinical validation in South Korea over the past two years, we are very excited about this large-scale clinical validation in the United States. We are committed to diligently completing the validation process as this would represent the first step towards wide use of PROTEINA SPID platform in providing PPI biomarkers for the emerging class of PPI-modulating drugs.”
Furthermore, through this project, PROTEINA aims to enhance the technological competitiveness of PPI PathFinder and the SPID platform and plans to supply the solution to overseas CLIA-certified labs based on the results of this exploratory clinical study.
About PROTEINA
Founded in 2015 in Seoul, PROTEINA is a leader in proteomics, enhancing drug research with its innovative Single-molecule Protein Interaction Detection (SPID) technology. This platform provides exceptional sensitivity for detecting protein-protein interactions, essential for pharmaceutical R&D. Serving top pharmaceutical companies and academic institutions worldwide, PROTEINA’s technology advances understanding of human biology, supporting modern healthcare solutions. With collaborations across Europe and North America, PROTEINA delivers insights that propel drug development and proteomic research.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428101218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
Andersen Consulting udvider sit udbud inden for cybersikkerhed og teknologi med tilføjelsen af Move18.9.2025 17:06:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Move, der er en førende virksomhed inden for it-infrastruktur, driftstjenester og digitale løsninger til virksomheder. Move befinder sig i Norge og Sverige. Move blev grundlagt i 1989 og leverer konsulentydelser, it-løsninger og driftstjenester. Virksomheden har ekspertise inden for cybersikkerhed, cloud-løsninger, server- og lagringsløsninger, netværkskommunikation og implementering af AI. Move samarbejder med mellemstore og store virksomheder om at designe, implementere og drive sikre, skalerbare og fremtidssikrede it-miljøer. "Dette samarbejde er en spændende mulighed for at skabe endnu større værdi for vores kunder," siger Roald Sannæs, der er administrerende direktør i Move. "Med vores kompetencer og Andersen Consultings globale rækkevidde og ekspertise kan vi levere mere helhedsorienterede løsninger, der hjælper organisationer med at løse nutidens udfordringer og forudse fremtidens muligheder." "Move har opbygget et godt ren
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 16:40:00 CEST | Press release
The inaugural ranking by TIME, in partnership with Statista, features AMRA as one of the world’s leading health technology companies that are “driving innovation, enhancing accessibility, and contributing to a more effective and sustainable health care system” AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom